Related Experiment Video

Updated: Feb 23, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Targeting acute myeloid leukemia with TP53-independent vosaroxin

Christopher B Benton1, Farhad Ravandi1

  • 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Future Oncology (London, England)
|September 13, 2016
PubMed

Insights

Vosaroxin, a DNA-intercalating agent, shows promise in treating acute myeloid leukemia (AML) by inducing cell death. Clinical trials indicate its efficacy, particularly when combined with cytarabine for relapsed or refractory AML.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Vosaroxin is a quinolone derivative with DNA-intercalating properties.
  • It induces TP53-independent apoptosis, a key mechanism in cancer cell death.
  • Vosaroxin has demonstrated activity in various phases of clinical trials for acute myeloid leukemia (AML).

Purpose of the Study:

  • To examine the mechanism of action and pharmacology of vosaroxin.
  • To review the clinical use of vosaroxin in acute myeloid leukemia (AML) to date.
  • To assess the role of vosaroxin in combination therapy for AML.

Main Methods:

  • Review of vosaroxin's mechanism of action, including DNA intercalation and apoptosis induction.
  • Analysis of data from Phase I-III clinical trials of vosaroxin in AML.
  • Focus on the randomized Phase III VALOR trial comparing vosaroxin plus cytarabine versus cytarabine alone.

Main Results:

  • Vosaroxin demonstrated activity against acute myeloid leukemia (AML) in Phase I-III trials.
  • The randomized Phase III VALOR trial showed improved outcomes for vosaroxin plus cytarabine in relapsed/refractory AML patients over 60 and in early relapse.
  • Vosaroxin's efficacy is linked to its DNA-intercalating and apoptosis-inducing properties.

Conclusions:

  • Vosaroxin is an active agent in the treatment of acute myeloid leukemia (AML).
  • Combination therapy with cytarabine shows significant benefit in specific AML patient populations.
  • Vosaroxin holds potential as part of a multifaceted strategy in evolving AML therapy.
Keywords:
acute myeloid leukemiaantineoplastic agentsintercalating agentsprospective studiesvosaroxin

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.5K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K